InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,598.60
(
-2.92%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: p3analyze post# 142396

Tuesday, 05/22/2012 11:17:13 PM

Tuesday, May 22, 2012 11:17:13 PM

Post# of 252504
I am beginning to wonder if ARQL sucks so incredibly badly because of this selected trial with MetMab. Isnt the Roche trial more highly selected than that of the ARQ trial? Granted, ARQ has a little head start on Roche but a targeted, more defined trial is going to have a chance of a higher degree of success, and better comp results.

http://www.roche.com/media/media_releases/med-cor-2011-05-19.htm

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up